Novartis sets 2020 target for commercial readiness of cell therapy CMO 10-Dec-2019 By Nick Taylor Novartis aims to have its Japanese cell therapy CMO commercially ready in the second half of 2020.
EMA approvals up, rejections down in 2018 11-Jan-2019 By Ben Hargreaves The EMA has provided its 2018 overview, which highlighted 84 positive opinions provided and five negative opinions.